{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:43:24Z","timestamp":1783763004745,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Fungal topoisomerase II (TopoII) has been identified as essential for viability. Thus, our research aimed to investigate the potential of fungal TopoII as a novel target for antifungal chemotherapy. We conducted studies on eleventh antitumor compounds targeting human topoisomerase II, either approved by the U.S. Food and Drug Administration (FDA) or currently under clinical trials to evaluate their potential for use in other therapeutic applications. While most of the compounds we analyzed are potent inhibitors of yeast TopoII, only a few exhibited antifungal activity. Idarubicin emerged as the most potent compound effectively inhibiting the growth of five reference fungal strains as well as clinical <jats:italic>Candida glabrata<\/jats:italic> fluconazole-resistant cells. Antifungal activity of this compound corresponded with its very high yeast TopoII inhibitory effectiveness. Additionally, idarubicin ability to be effectively accumulated into fungal cells is crucial for yeast TopoII targeting. Idarubicin, epirubicin, and bisantrene appeared to be even more effective inhibitors of yeast enzyme than its human counterpart. In fungal cells idarubicin exhibited a multifaceted mechanisms of action, including nuclear DNA fragmentation, disruption of mitochondrial network architecture and mitochondrial DNA aggregation as well as oxidative stress induction. Our results indicate that fungal topoisomerase II targeting is worth considering in antifungal treatment and the reported drugs may serve as a starting point for the reinnovation of a new molecule.<\/jats:p>","DOI":"10.1038\/s41598-025-93863-z","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T12:37:19Z","timestamp":1742301439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anticancer drugs targeting topoisomerase II for antifungal treatment"],"prefix":"10.1038","volume":"15","author":[{"given":"Kavya","family":"Kondaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Rz\u0105d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Maciejewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"93863_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/ciab336","volume":"74","author":"E Rayens","year":"2022","unstructured":"Rayens, E., Norris, K. A. & Cordero, J. F. Mortality trends in risk conditions and invasive mycotic disease in the united States, 1999\u20132018. Clin. Infect. Dis. 74, 309\u2013318 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"93863_CR2","doi-asserted-by":"crossref","unstructured":"Almeida, F., Rodrigues, M. L. & Coelho, C. The still underestimated problem of fungal diseases worldwide. Front. Microbiol. 10, 214 (2019).","DOI":"10.3389\/fmicb.2019.00214"},{"key":"93863_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.jiph.2021.10.010","volume":"14","author":"B Kuchi","year":"2021","unstructured":"Kuchi, B. Opportunistic mycoses in COVID-19 patients\/survivors: epidemic inside a pandemic. J. Infect. Public. Health. 14, 1720\u20131726 (2021).","journal-title":"J. Infect. Public. Health"},{"key":"93863_CR4","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1016\/S2213-2600(21)00265-4","volume":"9","author":"A Raut","year":"2021","unstructured":"Raut, A. & Huy, N. T. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second Wave?? Lancet Respir Med. 9, e77 (2021).","journal-title":"Lancet Respir Med."},{"key":"93863_CR5","unstructured":"WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"93863_CR6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1093\/cid\/ciab1070","volume":"75","author":"F Lamoth","year":"2022","unstructured":"Lamoth, F., Lewis, R. E. & Kontoyiannis, D. P. Investigational antifungal agents for invasive mycoses: A clinical perspective. Clin. Infect. Dis. 75, 534\u2013544 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"93863_CR7","doi-asserted-by":"crossref","unstructured":"Scorzoni, L. et al. Antifungal therapy: new advances in the Understanding and treatment of mycosis. Front. Microbiol. 8, 36 (2017).","DOI":"10.3389\/fmicb.2017.00036"},{"key":"93863_CR8","doi-asserted-by":"publisher","first-page":"5484","DOI":"10.1021\/acs.jmedchem.7b01413","volume":"61","author":"N Liu","year":"2018","unstructured":"Liu, N., Tu, J., Dong, G., Wang, Y. & Sheng, C. Emerging new targets for the treatment of resistant fungal infections. J. Med. Chem. 61, 5484\u20135511 (2018).","journal-title":"J. Med. Chem."},{"key":"93863_CR9","doi-asserted-by":"publisher","first-page":"14022","DOI":"10.3390\/molecules171214022","volume":"17","author":"MJ Milewska","year":"2012","unstructured":"Milewska, M. J., Prokop, M., Gabriel, I., MilewskiWojciechowski, M. & Milewski, S. Antifungal activity of homoaconitate and homoisocitrate analogs. Molecules 17, 14022\u201314036 (2012).","journal-title":"Molecules"},{"key":"93863_CR10","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00726-021-03007-6","volume":"53","author":"A Kupli\u0144ska","year":"2021","unstructured":"Kupli\u0144ska, A. & Rz\u0105d, K. Molecular targets for antifungals in amino acid and protein biosynthetic pathways. Amino Acids. 53, 961\u2013991 (2021).","journal-title":"Amino Acids"},{"key":"93863_CR11","doi-asserted-by":"publisher","first-page":"6602","DOI":"10.1016\/j.bmcl.2007.09.072","volume":"17","author":"A Melcer","year":"2007","unstructured":"Melcer, A. et al. Rational design of N-alkyl derivatives of 2-amino-2-deoxy-D-glucitol-6P as antifungal agents. Bioorg. Med. Chem. Lett. 17, 6602\u20136606 (2007).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"93863_CR12","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1080\/14756366.2020.1821676","volume":"35","author":"K Buzun","year":"2020","unstructured":"Buzun, K., Bielawska, A., Bielawski, K. & Gornowicz, A. DNA topoisomerases as molecular targets for anticancer drugs. J. Enzyme Inhib. Med. Chem. 35, 1781\u20131799 (2020).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"93863_CR13","doi-asserted-by":"publisher","first-page":"104266","DOI":"10.1016\/j.bioorg.2020.104266","volume":"104","author":"S Jaswal","year":"2020","unstructured":"Jaswal, S., Nehra, B., Kumar, S. & Monga, V. Recent advancements in the medicinal chemistry of bacterial type II topoisomerase inhibitors. Bioorg. Chem. 104, 104266 (2020).","journal-title":"Bioorg. Chem."},{"key":"93863_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0092-8674(85)80028-3","volume":"41","author":"C Holm","year":"1985","unstructured":"Holm, C., Goto, T., Wang, J. C. & Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41, 553\u2013563 (1985).","journal-title":"Cell"},{"key":"93863_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/0092-8674(87)90518-6","volume":"50","author":"T Uemura","year":"1987","unstructured":"Uemura, T. et al. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 50, 917\u2013925 (1987).","journal-title":"Cell"},{"key":"93863_CR16","doi-asserted-by":"publisher","first-page":"e2000286","DOI":"10.1002\/bies.202000286","volume":"43","author":"SJ Mckie","year":"2021","unstructured":"Mckie, S. J., Neuman, K. C. & Maxwell, A. DNA topoisomerases: advances in Understanding of cellular roles and multi-protein complexes via structure-function analysis. Bioessays 43, e2000286 (2021).","journal-title":"Bioessays"},{"key":"93863_CR17","doi-asserted-by":"publisher","first-page":"e105393","DOI":"10.15252\/embj.2020105393","volume":"40","author":"S Dyson","year":"2021","unstructured":"Dyson, S., Segura, J., Mart\u00ednez-Garc\u00eda, B., Vald\u00e9s, A. & Roca, J. Condensin minimizes topoisomerase II\u2010mediated entanglements of DNA in vivo. EMBO J. 40, e105393 (2021).","journal-title":"EMBO J."},{"key":"93863_CR18","doi-asserted-by":"publisher","first-page":"9243","DOI":"10.1093\/nar\/gkt707","volume":"41","author":"C Nikolaou","year":"2013","unstructured":"Nikolaou, C. et al. Topoisomerase II regulates yeast genes with singular chromatin architectures. Nucleic Acids Res. 41, 9243\u20139256 (2013).","journal-title":"Nucleic Acids Res."},{"key":"93863_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/ijms19010134","volume":"19","author":"RS Joshi","year":"2018","unstructured":"Joshi, R. S., Nikolaou, C. & Roca, J. Structure and chromosomal organization of yeast genes regulated by topoisomerase II. Int. J. Mol. Sci. 19, 134 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"93863_CR20","doi-asserted-by":"publisher","first-page":"7768","DOI":"10.3390\/molecules27227768","volume":"27","author":"K Kondaka","year":"2022","unstructured":"Kondaka, K. & Gabriel, I. Targeting DNA topoisomerase II in antifungal chemotherapy. Molecules 27, 7768\u20137783 (2022).","journal-title":"Molecules"},{"key":"93863_CR21","doi-asserted-by":"publisher","first-page":"11893","DOI":"10.1038\/s41598-023-38963-4","volume":"13","author":"K Rz\u0105d","year":"2023","unstructured":"Rz\u0105d, K. et al. Xanthone synthetic derivatives with high anticandidal activity and positive mycostatic selectivity index values. Sci. Rep. 13, 11893 (2023).","journal-title":"Sci. Rep."},{"key":"93863_CR22","doi-asserted-by":"publisher","first-page":"13190","DOI":"10.3390\/ijms222413190","volume":"22","author":"K Rz\u0105d","year":"2021","unstructured":"Rz\u0105d, K. et al. The effect of conjugation with octaarginine, a Cell-Penetrating peptide on antifungal activity of Imidazoacridinone derivative. Int. J. Mol. Sci. Artic. 22, 13190 (2021).","journal-title":"Int. J. Mol. Sci. Artic"},{"key":"93863_CR23","doi-asserted-by":"publisher","first-page":"127815","DOI":"10.1016\/j.bmcl.2021.127815","volume":"35","author":"K Rz\u0105d","year":"2021","unstructured":"Rz\u0105d, K., Paluszkiewicz, E. & Gabriel, I. A new 1-nitro-9-aminoacridine derivative targeting yeast topoisomerase II able to overcome fluconazole-resistance. Bioorg. Med. Chem. Lett. 35, 127815 (2021).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"93863_CR24","doi-asserted-by":"publisher","unstructured":"Rz\u0105d, K. et al. Targeting yeast topoisomerase II by Imidazo and Triazoloacridinone derivatives resulting in their antifungal activity. Sci. Rep. 1\u201319. https:\/\/doi.org\/10.1038\/s41598-024-54252-0 (2024).","DOI":"10.1038\/s41598-024-54252-0"},{"key":"93863_CR25","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1054-3589(08)61140-0","volume":"29","author":"LL Shen","year":"1994","unstructured":"Shen, L. L. & Fostel, J. M. DNA topoisomerase inhibitors as antifungal agents. Adv. Pharmacol. 29, 227\u2013244 (1994).","journal-title":"Adv. Pharmacol."},{"key":"93863_CR26","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1128\/AAC.36.12.2778","volume":"36","author":"LL Shen","year":"1992","unstructured":"Shen, L. L., Baranowski, J., Fostel, J., Montgomery, D. A. & Lartey, P. A. DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs. Antimicrob. Agents Chemother. 36, 2778\u20132784 (1992).","journal-title":"Antimicrob. Agents Chemother."},{"key":"93863_CR27","doi-asserted-by":"publisher","first-page":"21011","DOI":"10.1074\/jbc.M117.810580","volume":"292","author":"JH Lee","year":"2017","unstructured":"Lee, J. H., Wendorff, T. J., Berger, J. M. & Resveratrol A novel type of topoisomerase II inhibitor. J. Biol. Chem. 292, 21011\u201321022 (2017).","journal-title":"J. Biol. Chem."},{"key":"93863_CR28","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12088-021-00942-6","volume":"61","author":"D Andrade-Pav\u00f3n","year":"2021","unstructured":"Andrade-Pav\u00f3n, D. & G\u00f3mez-Garc\u00eda, O. Etoposide and camptothecin reduce growth, viability, the generation of Petite mutants, and recognize the active site of DNA topoisomerase I and II enzymes in Candida glabrata. Indian J. Microbiol. 61, 306\u2013314 (2021).","journal-title":"Indian J. Microbiol."},{"key":"93863_CR29","doi-asserted-by":"publisher","first-page":"foab023","DOI":"10.1093\/femsyr\/foab023","volume":"21","author":"T Tagle-Olmedo","year":"2021","unstructured":"Tagle-Olmedo, T. et al. Inhibitors of DNA topoisomerases I and II applied to Candida Dubliniensis reduce growth, viability, the generation of Petite mutants and toxicity, while acting synergistically with fluconazole. FEMS Yeast Res. 21, foab023 (2021).","journal-title":"FEMS Yeast Res."},{"key":"93863_CR30","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3109\/13693780903114934","volume":"48","author":"SC Kwok","year":"2010","unstructured":"Kwok, S. C., Schelenz, S., Wang, X. & Steverding, D. In vitro effect of DNA topoisomerase inhibitors on Candida albicans. Med. Mycol. 48, 155\u2013160 (2010).","journal-title":"Med. Mycol."},{"key":"93863_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3109\/13693786.2011.609186","volume":"50","author":"D Steverding","year":"2012","unstructured":"Steverding, D. et al. In vitro antifungal activity of DNA topoisomerase inhibitors. Med. Mycol. 50, 333\u2013336 (2012).","journal-title":"Med. Mycol."},{"key":"93863_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10096-008-0613-4","volume":"28","author":"U Kinnunen","year":"2009","unstructured":"Kinnunen, U., Syrj\u00e4l\u00e4, H., Koistinen, P. & Koskela, M. Idarubicin inhibits the growth of bacteria and yeasts in an automated blood culture system. Eur. J. Clin. Microbiol. Infect. Dis. 28, 301\u2013303 (2009).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"93863_CR33","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1128\/AAC.03083-14","volume":"58","author":"VV Kulkarny","year":"2014","unstructured":"Kulkarny, V. V. et al. Quinacrine inhibits Candida albicans growth and filamentation at neutral ph. Antimicrob. Agents Chemother. 58, 7501\u20137509 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"93863_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.mib.2017.10.020","volume":"40","author":"RA Hall","year":"2017","unstructured":"Hall, R. A. & Noverr, M. C. Fungal interactions with the human host: exploring the spectrum of symbiosis. Curr. Opin. Microbiol. 40, 58\u201364 (2017).","journal-title":"Curr. Opin. Microbiol."},{"key":"93863_CR35","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.3390\/ph16101456","volume":"16","author":"PA Yakkala","year":"2023","unstructured":"Yakkala, P. A., Penumallu, N. R., Shafi, S. & Kamal, A. Prospects of topoisomerase inhibitors as promising Anti-Cancer agents. Pharmaceuticals 16, 1456 (2023).","journal-title":"Pharmaceuticals"},{"key":"93863_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1054\/drup.2001.0201","volume":"4","author":"L Lothstein","year":"2001","unstructured":"Lothstein, L., Israel, M. & Sweatman, T. W. Anthracycline drug targeting: cytoplasmic versus nuclear - A fork in the road. Drug Resist. Updat. 4, 169\u2013177 (2001).","journal-title":"Drug Resist. Updat"},{"key":"93863_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00001813-199801000-00007","volume":"9","author":"L Lothstein","year":"1998","unstructured":"Lothstein, L., Rodrigues, P., Sweatman, T. & Israel, M. Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length. Anticancer Drugs. 9, 58\u201366 (1998).","journal-title":"Anticancer Drugs"},{"key":"93863_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: molecular advances and Pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185\u2013229 (2004).","journal-title":"Pharmacol. Rev."},{"key":"93863_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.semcancer.2019.09.021","volume":"68","author":"DB Oien","year":"2021","unstructured":"Oien, D. B. et al. Repurposing quinacrine for treatment-refractory cancer. Semin Cancer Biol. 68, 21\u201330 (2021).","journal-title":"Semin Cancer Biol."},{"key":"93863_CR40","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ejh.13544","volume":"106","author":"J Canaani","year":"2021","unstructured":"Canaani, J. et al. A phase II study of bisantrene in patients with relapsed\/refractory acute myeloid leukemia. Eur. J. Haematol. 106, 260\u2013266 (2021).","journal-title":"Eur. J. Haematol."},{"key":"93863_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1124\/jpet.115.228650","volume":"356","author":"BB Hasinoff","year":"2016","unstructured":"Hasinoff, B. B. et al. Mechanisms of action and reduced cardiotoxicity of Pixantrone; A topoisomerase II targeting agent with cellular selectivity for the topoisomerase IIa isoforms. J. Pharmacol. Exp. Ther. 356, 397\u2013409 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"93863_CR42","doi-asserted-by":"publisher","first-page":"18814","DOI":"10.1074\/jbc.M400931200","volume":"279","author":"BS Parker","year":"2004","unstructured":"Parker, B. S. et al. A molecular Understanding of mitoxantrone-DNA adduct formation: effect of cytosine methylation and flanking sequences. J. Biol. Chem. 279, 18814\u201318823 (2004).","journal-title":"J. Biol. Chem."},{"key":"93863_CR43","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1128\/AAC.44.10.2752-2758.2000","volume":"44","author":"R Ramani","year":"2000","unstructured":"Ramani, R. & Chaturvedi, V. Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test. Antimicrob. Agents Chemother. 44, 2752\u20132758 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"93863_CR44","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1099\/jmm.0.000062","volume":"64","author":"P Szweda","year":"2015","unstructured":"Szweda, P. et al. Mechanisms of Azole resistance among clinical isolates of Candida glabrata in Poland. J. Med. Microbiol. 64, 610\u2013619 (2015).","journal-title":"J. Med. Microbiol."},{"key":"93863_CR45","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1128\/EC.2.6.1361-1375.2003","volume":"2","author":"S Shukla","year":"2003","unstructured":"Shukla, S. et al. Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot. Cell. 2, 1361\u20131375 (2003).","journal-title":"Eukaryot. Cell."},{"key":"93863_CR46","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1128\/AAC.01497-08","volume":"53","author":"M Sharma","year":"2009","unstructured":"Sharma, M. et al. Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. Antimicrob. Agents Chemother. 53, 3256\u20133265 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"93863_CR47","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1128\/AAC.45.12.3366-3374.2001","volume":"45","author":"K Nakamura","year":"2001","unstructured":"Nakamura, K. et al. Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrob. Agents Chemother. 45, 3366\u20133374 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"93863_CR48","doi-asserted-by":"crossref","unstructured":"Martins-Teixeira, M. & Carvalho, I. Antitumour Anthracyclines: Progress and Perspectives. ChemMedChem 15, 933\u2013948 (202AD).","DOI":"10.1002\/cmdc.202000131"},{"key":"93863_CR49","doi-asserted-by":"publisher","first-page":"S553","DOI":"10.1177\/09603271211033774","volume":"40","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Idarubicin-induced oxidative stress and apoptosis in cardiomyocytes: an in vitro molecular approach. Hum. Exp. Toxicol. 40, S553\u2013S562 (2021).","journal-title":"Hum. Exp. Toxicol."},{"key":"93863_CR50","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1179\/135100000101535816","volume":"5","author":"P Moradas-Ferreira","year":"2000","unstructured":"Moradas-Ferreira, P. & Costa, V. Adaptive response of the yeast Saccharomyces cerevisiae to reactive oxygen species: defences, damage and death. Redox Rep. 5, 277\u2013285 (2000).","journal-title":"Redox Rep."},{"key":"93863_CR51","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.bbamcr.2008.08.003","volume":"1793","author":"SC Li","year":"2009","unstructured":"Li, S. C. & Kane, P. M. The yeast Lysosome-like vacuole: endpoint and crossroads. Biochim. Biophys. Acta. 1793, 650\u2013663 (2009).","journal-title":"Biochim. Biophys. Acta"},{"key":"93863_CR52","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/cdd.2009.219","volume":"17","author":"D Carmona-Gutierrez","year":"2010","unstructured":"Carmona-Gutierrez, D. et al. Apoptosis in yeast: triggers, pathways, subroutines. Cell. Death Differ. 17, 763\u2013773 (2010).","journal-title":"Cell. Death Differ."},{"key":"93863_CR53","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/j.1462-5822.2005.00616.x","volume":"7","author":"CA Kumamoto","year":"2005","unstructured":"Kumamoto, C. A. & Vinces, M. D. Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence. Cell. Microbiol. 7, 1546\u20131554 (2005).","journal-title":"Cell. Microbiol."},{"key":"93863_CR54","doi-asserted-by":"publisher","first-page":"e1002585","DOI":"10.1371\/journal.ppat.1002585","volume":"8","author":"S Fanning","year":"2012","unstructured":"Fanning, S. & Mitchell, A. P. Fungal biofilms. PLoS Pathog. 8, e1002585 (2012).","journal-title":"PLoS Pathog"},{"key":"93863_CR55","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2125.1987.tb03049.x","volume":"23","author":"HC Gilles","year":"1987","unstructured":"Gilles, H. C. et al. Pharmacokinetics of Idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br. J. Clin. Pharmacol. 23, 303\u2013310 (1987).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1\u20132","key":"93863_CR56","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jconrel.2005.03.007","volume":"105","author":"N Dos Santos","year":"2005","unstructured":"Dos Santos, N. et al. Substantial increases in Idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J. Control Release. 105 (1\u20132), 89\u2013105. https:\/\/doi.org\/10.1016\/j.jconrel.2005.03.007 (2005).","journal-title":"J. Control Release"},{"issue":"1","key":"93863_CR57","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jconrel.2010.05.021","volume":"146","author":"J Gubernator","year":"2010","unstructured":"Gubernator, J. et al. The encapsulation of Idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo. J. Control Release. 146 (1), 68\u201375 (2010).","journal-title":"J. Control Release"},{"issue":"4","key":"93863_CR58","first-page":"891","volume":"52","author":"AA Gabizon","year":"1992","unstructured":"Gabizon, A. A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52 (4), 891\u2013896 (1992).","journal-title":"Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93863-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93863-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93863-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T12:37:24Z","timestamp":1742301444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93863-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93863"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93863-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9311"}}